アルツハイマー病診断の世界市場レポート 2025年

アルツハイマー病診断市場規模は、今後数年で急成長が見込まれます。2029年には109億1,000万米ドルに成長し、CAGRは10.7%となります。予測期間の成長は、非侵襲的診断のための血液ベースのバイオマーカーの開発、個別化医療と精密診断の需要拡大、早期発見のための診断ツールへのAIと機械学習の統合、遠隔モニタリングと診断のためのデジタルヘルス技術の採用拡大、アクセス性向上のための新興国市場でのヘルスケアインフラの拡大などに起因すると考えられます。この期間に予想される主な動向には、画像診断、バイオマーカー、認知機能検査を組み合わせたマルチモーダル診断アプローチの出現、迅速な結果を得るためのポイントオブケア診断ソリューションへの注目の高まり、認知機能の健康を継続的にモニタリングするためのウェアラブルデバイスの開発、革新的なソリューションを目指したバイオテクノロジー企業と研究機関の協力関係の強化、アルツハイマー病リスク評価のための消費者直接遺伝子検査の成長などがあります。

慢性疾患の増加がアルツハイマー病診断市場の成長を牽引すると予測されます。慢性疾患とは、3カ月以上持続する長期的な健康状態を指します。慢性疾患の有病率の増加は、ライフスタイルの選択、環境要因、遺伝的素因、社会経済的条件など、相互に関連するいくつかの要因の影響を受けています。心血管疾患、糖尿病、高血圧などの慢性疾患の存在は、アルツハイマー病（AD）やその他の認知症の発症リスクを高める。例えば、2022年1月、米国の非営利任意団体である米国心臓協会（American Heart Association Inc.）の報告書によると、米国における脳疾患は2060年までに930万人に増加すると予想され、現在その数は増加しています。さらに、世界では6人に1人が脳疾患に罹患しており、2021年には世界で約10億人が脳疾患に罹患しています。その結果、慢性疾患の有病率の増加がアルツハイマー病診断市場の成長を促進すると予想されます。

アルツハイマー病診断市場の主要企業は、アルツハイマー病の診断プロセスを合理化すると期待される血液ベースのバイオマーカー検査の進歩を優先しています。これらの進歩は、より侵襲的な処置への依存を減らし、患者のタイムリーな治療へのアクセスを強化することを目的としています。例えば、2023年10月、米国のバイオテクノロジー研究会社であるQuanterix社は、血液検査において高い臨床感度と特異性を提供するアルツハイマー病病態のバイオマーカーであるLucentAD p-Tau 217検査を発表しました。従来の脳脊髄液（CSF）バイオマーカー分析法では、陽電子放射断層撮影（PET）スキャンや腰椎穿刺が行われているが、いずれもコストが高く、侵襲的であり、広く利用されていないです。この新しい検査は、Quanterix社の超高感度SimoaOテクノロジーとJ&J Innovative Medicine社の広範囲に検査されたp-Tau 217抗体を統合したもので、高い精度とより簡単な診断プロセスを保証します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界アルツハイマー病診断 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のアルツハイマー病診断市場：成長率分析
• 世界のアルツハイマー病診断市場の実績：規模と成長, 2019-2024
• 世界のアルツハイマー病診断市場の予測：規模と成長, 2024-2029, 2034F
• 世界アルツハイマー病診断総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のアルツハイマー病診断市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トリアージ
• 診断
• スクリーニング
• 世界のアルツハイマー病診断市場診断技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイオマーカー
• 画像技術
• 遺伝子検査
• 認知評価テスト
• 世界のアルツハイマー病診断市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 病院
• 診断センター
• 製薬会社
• 学術研究センター
• 世界のアルツハイマー病診断市場、トリアージのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 認知テスト
• 画像技術
• 世界のアルツハイマー病診断市場、診断のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイオマーカー検査
• 神経画像検査
• 世界のアルツハイマー病診断市場、スクリーニングのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 神経心理学的検査
• 遺伝子検査

第7章 地域別・国別分析

• 世界のアルツハイマー病診断市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のアルツハイマー病診断市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• アルツハイマー病診断市場：競合情勢
• アルツハイマー病診断市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Hoffmann-La Roche Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Siemens Healthineers AG
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Daiichi Sankyo Co.
• Sysmex
• Lantheus
• Quanterix
• FujireBio
• TauRx Pharmaceuticals Ltd
• AC Immune
• C2N diagnostics
• AXON Neuroscience
• Neuro-Bio Ltd
• Anavex Life Sciences Corp.
• Treventis Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• アルツハイマー病診断市場2029：新たな機会を提供する国
• アルツハイマー病診断市場2029：新たな機会を提供するセグメント
• アルツハイマー病診断市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Alzheimer's disease diagnostics involve methods and tools used to detect and confirm the presence of Alzheimer's, a progressive neurodegenerative disorder. These diagnostics include cognitive assessments, imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, and biomarker tests that analyze cerebrospinal fluid (CSF) or blood for amyloid-beta and tau proteins.

The primary types of Alzheimer's disease diagnostics include triage, diagnosis, and screening. Triage is a systematic method for prioritizing patients based on the urgency and severity of their cognitive symptoms. Diagnostic techniques encompass biomarkers, imaging techniques, genetic testing, and cognitive assessment tests. These are utilized by various end users, including clinics, hospitals, diagnostic centers, pharmaceutical companies, and academic research centers.

The alzheimer's disease diagnostic market research report is one of a series of new reports from The Business Research Company that provides alzheimer's disease diagnostic market statistics, including alzheimer's disease diagnostic industry global market size, regional shares, competitors with a alzheimer's disease diagnostic market share, detailed alzheimer's disease diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the alzheimer's disease diagnostic industry. This alzheimer's disease diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alzheimer's disease diagnostic market size has grown rapidly in recent years. It will grow from $6.56 billion in 2024 to $7.28 billion in 2025 at a compound annual growth rate (CAGR) of 11%. The growth during the historic period can be attributed to the rising prevalence of Alzheimer's disease and dementia, increasing awareness of the importance of early diagnosis for better management, advancements in imaging technologies such as MRI and PET scans, growing investment in research and development for neurodegenerative diseases, and government initiatives and funding for Alzheimer's research and diagnostics.

The alzheimer's disease diagnostic market size is expected to see rapid growth in the next few years. It will grow to $10.91 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to the development of blood-based biomarkers for non-invasive diagnosis, increasing demand for personalized medicine and precision diagnostics, the integration of AI and machine learning in diagnostic tools for early detection, the growing adoption of digital health technologies for remote monitoring and diagnosis, and the expansion of healthcare infrastructure in emerging markets to improve accessibility. Key trends expected during this period include the emergence of multi-modal diagnostic approaches combining imaging, biomarkers, and cognitive tests, a rising focus on point-of-care diagnostic solutions for faster results, the development of wearable devices for continuous monitoring of cognitive health, increased collaborations between biotech companies and research institutions for innovative solutions, and the growth of direct-to-consumer genetic testing for Alzheimer's risk assessment.

The rise in chronic diseases is anticipated to drive the growth of the Alzheimer's disease diagnostic market. Chronic disease refers to a long-term health condition that persists for more than three months. The increasing prevalence of chronic diseases is influenced by several interconnected factors, including lifestyle choices, environmental factors, genetic predisposition, and socioeconomic conditions. The presence of chronic conditions such as cardiovascular issues, diabetes, and hypertension elevates the risk of developing Alzheimer's disease (AD) and other forms of dementia. For example, in January 2022, a report by the American Heart Association Inc., a US-based nonprofit voluntary organization, stated that brain disorders in the US are expected to increase to 9.3 million by 2060, with the number currently growing. Additionally, one in every six people worldwide suffers from a brain disease, and by 2021, approximately 1 billion people globally were affected by brain disorders. As a result, the increasing prevalence of chronic diseases is expected to drive the growth of the Alzheimer's disease diagnostic market.

Leading companies in the Alzheimer's disease diagnostic market are prioritizing advancements in blood-based biomarker tests, which are expected to streamline the diagnostic process for Alzheimer's disease. These advancements aim to reduce dependence on more invasive procedures and enhance access to timely treatment for patients. For example, in October 2023, Quanterix, a US-based biotechnology research company, introduced the LucentAD p-Tau 217 test, a biomarker for Alzheimer's pathology that offers high clinical sensitivity and specificity in blood testing. Traditional methods for cerebrospinal fluid (CSF) biomarker analysis involve positron emission tomography (PET) scans or lumbar punctures, both of which are costly, invasive, and not widely accessible. The new test integrates Quanterix's ultra-sensitive SimoaO technology with J&J Innovative Medicine's extensively tested p-Tau 217 antibodies, ensuring high accuracy and a more straightforward diagnostic process.

In July 2024, Lantheus, a US-based radiopharmaceutical company, acquired Meilleur Technologies for an undisclosed amount. This acquisition is aimed at expanding Lantheus' portfolio of PET imaging agents for Alzheimer's disease. Meilleur Technologies, a US-based biopharmaceutical company, has collaborated with research institutions to develop imaging biomarkers for Alzheimer's disease.

Major players in the alzheimer's disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., and Treventis Corporation.

North America was the largest region in the alzheimer's disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in alzheimer's disease diagnostic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the alzheimer's disease diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alzheimer's disease diagnostic market consists of revenues earned by entities by providing services such as cognitive assessment tests, genetic tests, biomarker tests, and cerebrospinal fluid analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The alzheimer's disease diagnostic market also includes sales of genetic testing kits, cognitive assessment tools, imaging equipment, biomarker kits, and wearable devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alzheimer's Disease Diagnostic Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alzheimer's disease diagnostic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alzheimer's disease diagnostic ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alzheimer's disease diagnostic market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Triage; Diagnosis; Screening
• 2) By Diagnostic Technique: Biomarkers; Imaging Techniques; Genetic Testing; Cognitive Assessment Tests
• 3) By End User: Clinics; Hospitals; Diagnostic Centers; Pharmaceutical Companies; Academic Research Center
• Subsegments:
• 1) By Triage: Cognitive Testing; Imaging Techniques
• 2) By Diagnosis: Biomarker Testing; Neuroimaging
• 3) By Screening: Neuropsychological Testing; Genetic Testing
• Companies Mentioned: Pfizer Inc.; AbbVie; Bristol Myers Squibb Company; Hoffmann-La Roche; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Alzheimer's Disease Diagnostic Market Characteristics

3. Alzheimer's Disease Diagnostic Market Trends And Strategies

4. Alzheimer's Disease Diagnostic Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Alzheimer's Disease Diagnostic Growth Analysis And Strategic Analysis Framework

• 5.1. Global Alzheimer's Disease Diagnostic PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Alzheimer's Disease Diagnostic Market Growth Rate Analysis
• 5.4. Global Alzheimer's Disease Diagnostic Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Alzheimer's Disease Diagnostic Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Alzheimer's Disease Diagnostic Total Addressable Market (TAM)

6. Alzheimer's Disease Diagnostic Market Segmentation

• 6.1. Global Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triage
• Diagnosis
• Screening
• 6.2. Global Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biomarkers
• Imaging Techniques
• Genetic Testing
• Cognitive Assessment Tests
• 6.3. Global Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• Diagnostic Centers
• Pharmaceutical Companies
• Academic Research Center
• 6.4. Global Alzheimer's Disease Diagnostic Market, Sub-Segmentation Of Triage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cognitive Testing
• Imaging Techniques
• 6.5. Global Alzheimer's Disease Diagnostic Market, Sub-Segmentation Of Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biomarker Testing
• Neuroimaging
• 6.6. Global Alzheimer's Disease Diagnostic Market, Sub-Segmentation Of Screening, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neuropsychological Testing
• Genetic Testing

7. Alzheimer's Disease Diagnostic Market Regional And Country Analysis

• 7.1. Global Alzheimer's Disease Diagnostic Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Alzheimer's Disease Diagnostic Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Alzheimer's Disease Diagnostic Market

• 8.1. Asia-Pacific Alzheimer's Disease Diagnostic Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Alzheimer's Disease Diagnostic Market

• 9.1. China Alzheimer's Disease Diagnostic Market Overview
• 9.2. China Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Alzheimer's Disease Diagnostic Market

• 10.1. India Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Alzheimer's Disease Diagnostic Market

• 11.1. Japan Alzheimer's Disease Diagnostic Market Overview
• 11.2. Japan Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Alzheimer's Disease Diagnostic Market

• 12.1. Australia Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Alzheimer's Disease Diagnostic Market

• 13.1. Indonesia Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Alzheimer's Disease Diagnostic Market

• 14.1. South Korea Alzheimer's Disease Diagnostic Market Overview
• 14.2. South Korea Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Alzheimer's Disease Diagnostic Market

• 15.1. Western Europe Alzheimer's Disease Diagnostic Market Overview
• 15.2. Western Europe Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Alzheimer's Disease Diagnostic Market

• 16.1. UK Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Alzheimer's Disease Diagnostic Market

• 17.1. Germany Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Alzheimer's Disease Diagnostic Market

• 18.1. France Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Alzheimer's Disease Diagnostic Market

• 19.1. Italy Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Alzheimer's Disease Diagnostic Market

• 20.1. Spain Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Alzheimer's Disease Diagnostic Market

• 21.1. Eastern Europe Alzheimer's Disease Diagnostic Market Overview
• 21.2. Eastern Europe Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Alzheimer's Disease Diagnostic Market

• 22.1. Russia Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Alzheimer's Disease Diagnostic Market

• 23.1. North America Alzheimer's Disease Diagnostic Market Overview
• 23.2. North America Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Alzheimer's Disease Diagnostic Market

• 24.1. USA Alzheimer's Disease Diagnostic Market Overview
• 24.2. USA Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Alzheimer's Disease Diagnostic Market

• 25.1. Canada Alzheimer's Disease Diagnostic Market Overview
• 25.2. Canada Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Alzheimer's Disease Diagnostic Market

• 26.1. South America Alzheimer's Disease Diagnostic Market Overview
• 26.2. South America Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Alzheimer's Disease Diagnostic Market

• 27.1. Brazil Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Alzheimer's Disease Diagnostic Market

• 28.1. Middle East Alzheimer's Disease Diagnostic Market Overview
• 28.2. Middle East Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Alzheimer's Disease Diagnostic Market

• 29.1. Africa Alzheimer's Disease Diagnostic Market Overview
• 29.2. Africa Alzheimer's Disease Diagnostic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Alzheimer's Disease Diagnostic Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Alzheimer's Disease Diagnostic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Alzheimer's Disease Diagnostic Market Competitive Landscape And Company Profiles

• 30.1. Alzheimer's Disease Diagnostic Market Competitive Landscape
• 30.2. Alzheimer's Disease Diagnostic Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Hoffmann-La Roche Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Alzheimer's Disease Diagnostic Market Other Major And Innovative Companies

• 31.1. Siemens Healthineers AG
• 31.2. Laboratory Corporation of America Holdings
• 31.3. Quest Diagnostics Incorporated
• 31.4. Daiichi Sankyo Co.
• 31.5. Sysmex
• 31.6. Lantheus
• 31.7. Quanterix
• 31.8. FujireBio
• 31.9. TauRx Pharmaceuticals Ltd
• 31.10. AC Immune
• 31.11. C2N diagnostics
• 31.12. AXON Neuroscience
• 31.13. Neuro-Bio Ltd
• 31.14. Anavex Life Sciences Corp.
• 31.15. Treventis Corporation

32. Global Alzheimer's Disease Diagnostic Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Alzheimer's Disease Diagnostic Market

34. Recent Developments In The Alzheimer's Disease Diagnostic Market

35. Alzheimer's Disease Diagnostic Market High Potential Countries, Segments and Strategies

• 35.1 Alzheimer's Disease Diagnostic Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Alzheimer's Disease Diagnostic Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Alzheimer's Disease Diagnostic Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer